{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:08:17Z","timestamp":1768316897145,"version":"3.49.0"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Drugs blocking the renin\u2013angiotensin\u2013aldosterone system may offer benefit on endothelial function, inflammation, and hemostasis in addition to the effects of reducing blood pressure. We examined the contribution of the angiotensin-converting enzyme inhibitor ramipril and the alpha 1-adrenergic receptor blocker doxazosin on blood pressure and on markers of inflammation and hemostasis in 59 individuals with mild-to-moderate hypertension randomized to receive double-blind ramipril 10 mg od or doxazosin 8 mg od for 12 weeks. Inflammatory markers (interleukin-6, soluble interleukin-6 receptor, interleukin-8, tumor necrosis factor-\u03b1, monocyte chemoattractant protein-1, and C-reactive protein) and hemostasis (plasminogen activator inhibitor-1 activity, tissue plasminogen activator antigen, thrombin-antithrombin complex, and thrombin generation by calibrated automated thrombogram) were assessed. The treatment reduced blood pressure in both groups. Thrombin-antithrombin complex decreased by treatment, and this was dependent on a reduction in thrombin-antithrombin complex in the ramipril group alone. There were no changes in plasminogen activator inhibitor-1 activity, whereas tissue plasminogen activator antigen increased by ramipril and decreased by doxazosin. Only minor changes were observed in systemic inflammation by treatment. Treatment with ramipril seems to reduce thrombin generation beyond effects on reducing blood pressure. Drugs blocking the renin\u2013angiotensin\u2013aldosterone system may reduce atherothrombotic complications beyond their effects to reduce blood pressure.<\/jats:p>","DOI":"10.1097\/fjc.0000000000000565","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T17:50:13Z","timestamp":1517421013000},"page":"240-247","source":"Crossref","is-referenced-by-count":12,"title":["Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension"],"prefix":"10.1097","volume":"71","author":[{"given":"Mikael","family":"Ekholm","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Jekell","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. H\u00e5kan","family":"Wall\u00e9n","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Gigante","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden; and"},{"name":"Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kahan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/CIRCULATIONAHA.112.093245","article-title":"The assessment of endothelial function: from research into clinical practice","volume":"126","author":"Flammer","year":"2012","journal-title":"Circulation"},{"key":"R2-20230911","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis-an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med."},{"key":"R3-20230911","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1046\/j.1523-1755.62.s82.4.x","article-title":"Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney","author":"Ruiz-Ortega","year":"2002","journal-title":"Kidney Int Suppl."},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.thromres.2008.12.040","article-title":"Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo","volume":"124","author":"Ekholm","year":"2009","journal-title":"Thromb Res."},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/1470320315575848","article-title":"Haemostatic and inflammatory alterations in familial hypercholesterolaemia, and the impact of angiotensin II infusion","volume":"16","author":"Ekholm","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst."},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001721-199901000-00003","article-title":"Acute effects of angiotensin II on fibrinolysis in healthy volunteers","volume":"10","author":"Larsson","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MBC.0000000000000393","article-title":"Infusion of angiotensin II increases fibrinolysis in healthy individuals but not in patients with familial combined hyperlipidemia","volume":"27","author":"Ekholm","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1081\/CEH-120027328","article-title":"Short-term effects of exogenous angiotensin II on plasma fibrinolytic balance in normal subjects","volume":"26","author":"Lottermoser","year":"2004","journal-title":"Clin Exp Hypertens."},{"key":"R9-20230911","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J."},{"key":"R10-20230911","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1161\/01.HYP.0000070956.57418.22","article-title":"Different effect of antihypertensive drugs on conduit artery endothelial function","volume":"41","author":"Ghiadoni","year":"2003","journal-title":"Hypertension"},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1161\/01.CIR.102.12.1388","article-title":"Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease","volume":"102","author":"Brilla","year":"2000","journal-title":"Circulation"},{"key":"R12-20230911","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1042\/cs1030151","article-title":"Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension","volume":"103","author":"Ekholm","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"R13-20230911","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/10641960500511570","article-title":"Effect of doxazosin on oxidative stress related proteins in essential hypertensive patients","volume":"28","author":"Calo","year":"2006","journal-title":"Clin Exp Hypertens."},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0895-7061(01)02141-0","article-title":"Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients","volume":"14","author":"Hirano","year":"2001","journal-title":"Am J Hypertens."},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0895-7061(00)01263-2","article-title":"Doxazosin, an alpha1-adrenergic antihypertensive agent, decreases serum oxidized LDL","volume":"14","author":"Kinoshita","year":"2001","journal-title":"Am J Hypertens."},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF00403280","article-title":"Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis","volume":"34","author":"Juhan-Vague","year":"1991","journal-title":"Diabetologia"},{"key":"R17-20230911","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2011.02.044","article-title":"Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials","volume":"216","author":"Shahin","year":"2011","journal-title":"Atherosclerosis"},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"e90217","DOI":"10.1371\/journal.pone.0090217","article-title":"Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"R19-20230911","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00380-016-0924-9","article-title":"The effects of alpha 1-adrenoceptor blockade and angiotensin converting enzyme inhibition on central and brachial blood pressure and vascular reactivity: the doxazosin-ramipril study","volume":"32","author":"Jekell","year":"2016","journal-title":"Heart Vessels"},{"key":"R20-20230911","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1160\/TH06-07-0408","article-title":"Thrombin generation, a function test of the haemostatic-thrombotic system","volume":"96","author":"Hemker","year":"2006","journal-title":"Thromb Haemost."},{"key":"R21-20230911","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/01.HYP.34.2.285","article-title":"Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans","volume":"34","author":"Brown","year":"1999","journal-title":"Hypertension"},{"key":"R22-20230911","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.thromres.2005.04.033","article-title":"Angiotensin II induces the expression of tissue factor and its mechanism in human monocytes","volume":"117","author":"He","year":"2006","journal-title":"Thromb Res."},{"key":"R23-20230911","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0002-9149(03)00657-X","article-title":"Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage\/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT])","volume":"92","author":"Felmeden","year":"2003","journal-title":"Am J Cardiol."},{"key":"R24-20230911","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1161\/ATVBAHA.110.222703","article-title":"Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I\/NADPH oxidase\/Rho kinase pathways targeted to lipid rafts","volume":"31","author":"Burger","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"R25-20230911","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.thromres.2013.01.019","article-title":"Angiotensin II induces the generation of procoagulant microparticles by human mononuclear cells via an angiotensin type 2 receptor-mediated pathway","volume":"131","author":"Cordazzo","year":"2013","journal-title":"Thromb Res."},{"key":"R26-20230911","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0735-1097(99)00318-6","article-title":"Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction","volume":"34","author":"Soejima","year":"1999","journal-title":"J Am Coll Cardiol."},{"key":"R27-20230911","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/01.RES.86.2.139","article-title":"Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes","volume":"86","author":"Napoleone","year":"2000","journal-title":"Circ Res."},{"key":"R28-20230911","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med."},{"key":"R29-20230911","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/S0140-6736(01)07186-0","article-title":"Blood-pressure reduction and cardiovascular risk in HOPE study","volume":"358","author":"Sleight","year":"2001","journal-title":"Lancet"},{"key":"R30-20230911","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bjhh.2017.03.009","article-title":"Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations","volume":"39","author":"Duarte","year":"2017","journal-title":"Rev Bras Hematol Hemoter."},{"key":"R31-20230911","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ehj.2003.11.004","article-title":"Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis","volume":"25","author":"Lowe","year":"2004","journal-title":"Eur Heart J."},{"key":"R32-20230911","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1160\/th14-03-0199","article-title":"The relevance of coagulation in cardiovascular disease: what do the biomarkers tell us?","volume":"112","author":"Lowe","year":"2014","journal-title":"Thromb Haemost."},{"key":"R33-20230911","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1161\/01.CIR.102.18.2190","article-title":"Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway","volume":"102","author":"Brown","year":"2000","journal-title":"Circulation"},{"key":"R34-20230911","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2005.05.038","article-title":"Clots, kinins and coronaries","volume":"183","author":"Cruden","year":"2005","journal-title":"Atherosclerosis"},{"key":"R35-20230911","doi-asserted-by":"crossref","first-page":"168s","DOI":"10.1093\/ajh\/4.2.168S","article-title":"Decreased fibrinolytic activity and increased platelet function in hypertension. Possible influence of calcium antagonism","volume":"4","author":"Gleerup","year":"1991","journal-title":"Am J Hypertens."},{"key":"R36-20230911","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2796.1990.tb00157.x","article-title":"Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease","volume":"227","author":"Landin","year":"1990","journal-title":"J Intern Med."},{"key":"R37-20230911","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2796.1991.tb00352.x","article-title":"Hypo-fibrinolysis in patients with hypertension and elevated cholesterol","volume":"229","author":"Jansson","year":"1991","journal-title":"J Intern Med."},{"key":"R38-20230911","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ajh\/1.2.158","article-title":"Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension","volume":"1","author":"Cubeddu","year":"1988","journal-title":"Am J Hypertens."},{"key":"R39-20230911","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ajh\/5.11.827","article-title":"Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension","volume":"5","author":"Shieh","year":"1992","journal-title":"Am J Hypertens."},{"key":"R40-20230911","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0002-8703(96)90312-9","article-title":"Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance","volume":"132","author":"Jeng","year":"1996","journal-title":"Am Heart J."},{"key":"R41-20230911","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/FJC.0000000000000017","article-title":"Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study","volume":"62","author":"Jekell","year":"2013","journal-title":"J Cardiovasc Pharmacol."},{"key":"R42-20230911","doi-asserted-by":"crossref","first-page":"406960","DOI":"10.1155\/2014\/406960","article-title":"Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension","volume":"2014","author":"Dinh","year":"2014","journal-title":"Biomed Res Int."},{"key":"R43-20230911","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20110340","article-title":"IL-6\/IL-6 receptor system and its role in physiological and pathological conditions","volume":"122","author":"Mihara","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"R44-20230911","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol."},{"key":"R45-20230911","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int J Biol Sci."},{"key":"R46-20230911","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0022-2143(96)90005-0","article-title":"In vivo, in vitro, and molecular aspects of interleukin-8 and the interleukin-8 receptors","volume":"128","author":"Hoch","year":"1996","journal-title":"J Lab Clin Med."},{"key":"R47-20230911","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.ATV.0000134294.54422.2e","article-title":"IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study","volume":"24","author":"Boekholdt","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"R48-20230911","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1161\/01.CIR.96.9.3042","article-title":"Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo","volume":"96","author":"Bhagat","year":"1997","journal-title":"Circulation"},{"key":"R49-20230911","first-page":"272","article-title":"Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus","volume":"84","author":"Zinman","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"R50-20230911","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1172\/JCI117936","article-title":"Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance","volume":"95","author":"Hotamisligil","year":"1995","journal-title":"J Clin Invest."},{"key":"R51-20230911","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/hy0202.103290","article-title":"Effect of TNF-alpha\u2013converting enzyme inhibitor on insulin resistance in fructose-fed rats","volume":"39","author":"Togashi","year":"2002","journal-title":"Hypertension"},{"key":"R52-20230911","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0021-9150(98)00318-9","article-title":"Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice","volume":"143","author":"Dawson","year":"1999","journal-title":"Atherosclerosis"},{"key":"R53-20230911","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J Interferon Cytokine Res."},{"key":"R54-20230911","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1172\/JCI118623","article-title":"Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH\/NADPH oxidase activation. Contribution to alterations of vasomotor tone","volume":"97","author":"Rajagopalan","year":"1996","journal-title":"J Clin Invest."},{"key":"R55-20230911","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1161\/01.RES.81.5.804","article-title":"Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin","volume":"81","author":"Grafe","year":"1997","journal-title":"Circ Res."},{"key":"R56-20230911","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1042\/cs1030131","article-title":"Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1","volume":"103","author":"Jilma","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"R57-20230911","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/00005344-200105000-00005","article-title":"Doxazosin inhibits monocyte chemotactic protein 1-directed migration of human monocytes","volume":"37","author":"Kintscher","year":"2001","journal-title":"J Cardiovasc Pharmacol."},{"key":"R58-20230911","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/01.ATV.19.4.972","article-title":"C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?","volume":"19","author":"Yudkin","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"R59-20230911","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/HJH.0b013e3283617310","article-title":"Inhibition of the renin-angiotensin system does not reduce platelet activity at rest or during stress in hypertension","volume":"31","author":"Schwieler","year":"2013","journal-title":"J Hypertens."},{"key":"R60-20230911","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/01.fjc.0000211743.93701.eb","article-title":"Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension","volume":"47","author":"Derosa","year":"2006","journal-title":"J Cardiovasc Pharmacol."}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005344-201804000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T01:16:19Z","timestamp":1694394979000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005344-201804000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000000565","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}